Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist II, Analytical Development

Employer
Precision BioSciences, Inc.
Location
Durham, NC, United States
Start date
Sep 7, 2021

View more

Job Details

The Scientist II, Analytical Development Gene Therapy Analytics will develop physiochemical methods designed at characterizing and/or measuring the critical quality attributes (CQAs) of cell and gene therapy products. They will be responsible for independently designing and executing laboratory experiments, compiling relevant findings into reports, and presenting results to internal and external stakeholders. The successful candidate will be comfortable working in a dynamic, cross-functional, work environment.

**Please note, Precision BioSciences mandates COVID-19 vaccination of all employees. Accommodations may be made in accordance with applicable law.

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.
  • Development and support of CE methods to for the analysis of proteins, oligonucleotides, and carbohydrates from gene therapy products.
  • Development and support of HPLC/UPLC methods (SEC, IEX, and RP using UV, FLR, and CAD) to measure the CQAs of cell and gene therapy products
  • Testing of in-process, drug substance, and drug product samples using CE and HPLC/UPLC
  • Participating in tech transfer protocols to transfer developed methods and acquired knowledge to the QC team
  • Authoring and reviewing analytical test methods, protocols, and technical reports
  • Engaging with internal and external stakeholders/customers to set strategic goals, generate workplans, and discuss findings


Qualifications

The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.

Required:
  • PhD in Biochemistry, Analytical Chemistry or a related discipline with 2+ years of industry experience or Masters degree in Biochemistry, Analytical Chemistry or a related discipline with 6+ years of industry experience or BS in Biochemistry, Analytical Chemistry or a related discipline with 11+ years of industry experience or equivalent combination of education and experience
  • Demonstrated ability to develop CE and HPLC/UPLC methods to characterize or measure the CQAs of in-process, drug substance, and drug product samples
  • Thorough understanding of Quality by Design (QbD)
  • Use of excellent oral and written communication skills to present findings to a broader scientific audience and to author technical documents (protocols, reports, and SOPs)
  • Success working in a dynamic, cross-functional environment


Preferred:
  • Experience developing methods for cell and gene therapy products
  • Experience with the following techniques: DLS, DSC, AUC, ITC, large molecule LC-MS, and MALS
  • Experience working in a GMP environment
  • Previous people leadership or mentoring experience


Travel Requirements
  • This position may require up to 10 % travel


Location
  • This is an office-based position located at the main headquarters in downtown Durham, NC.


Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. This isnt just a statement supporting the products that were developing its a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com

Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Company

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Company info
Website
Phone
919-314-5512
Location
302 East Pettigrew Street
Durham
North Carolina
27701
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert